FDA Reviewers Pan Tolvaptan Trial Results

WASHINGTON (MedPage Today) -- FDA staff reviewers aren't ready to endorse tolvaptan (Samsca) to treat autosomal dominant polycystic kidney disease, citing missing clinical trial data, they said ahead of an advisory committee meeting to consider the drug.
Source: MedPage Today Primary Care - Category: Primary Care Source Type: news